Zobrazeno 1 - 10
of 51
pro vyhledávání: '"A G, Manikhas"'
Publikováno v:
Сибирский онкологический журнал, Vol 23, Iss 1, Pp 36-44 (2024)
Background. Breast cancer is the most common cancer in women. The main treatment for breast cancer includes surgery, chemotherapy, radiation therapy, and hormone therapy. The role of radiation therapy in the management of breast cancer continues to e
Externí odkaz:
https://doaj.org/article/c9a7d1ba53824eb5ae725d5b153aa56e
Autor:
Liudmila G. Zhukova, Larisa V. Bolotina, Victoria V. Dvornichenko, Natalia V. Fadeeva, Inna P. Ganshina, Katerina S. Grechukhina, Alfiya I. Hasanova, Nikolay V. Kislov, Igor Yu. Kudryavtsev, Alexey G. Manikhas, Natalia E. Musaeva, Alexandra A. Nizhegorodtseva, Olga E. Sadikova, Dina D. Sakaeva, Anton V. Snegovoy, Daniil L. Stroyakovskiy, Sergei A. Tjulandin, Ekaterina A. Trishkina, Liubov Iu. Vladimirova, Nikita M. Volkov, Yulia V. Kostalanova
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 56-64 (2024)
Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. The approval studies MONALEESA-2 and 7 demonstra
Externí odkaz:
https://doaj.org/article/38d513dc74f248e7bd74c0e83c57a19a
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 2, Pp 14-20 (2022)
Background. Comprehensive treatment of breast cancer includes surgery, radiation therapy and systemic treatment. Radiation therapy plays an integral role in the treatment of early breast cancer. The appointment of a targeted dose of radiation to the
Externí odkaz:
https://doaj.org/article/c4e50f2ef24f4f46b1d8bd74426da182
Publikováno v:
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, Vol 28, Iss 4, Pp 48-55 (2022)
Introduction. Elderly and senile patients are a special category of patients and standard methods in breast cancer treatment are not suitable due to the frequent presence of serious comorbidities and personal preferences and concerns about treatment
Externí odkaz:
https://doaj.org/article/17774a4c6274400aa74648925d76a1ea
Autor:
L. A. Tashireva, N. O. Popova, V. V. Alifanov, V. E. Goldberg, E. I. Kovalenko, E. V. Artamonova, A. G. Manikhas, D. M. Ponomarenko, N. V. Levchenko, E. I. Rossokha, S. Yu. Krasilnikova, M. A. Zafirova, V. M. Perelmuter
Publikováno v:
Опухоли женской репродуктивной системы, Vol 17, Iss 4, Pp 48-55 (2022)
Background. Triple negative breast cancer has no specific treatment sites for chemotherapy and is unfavorable in terms of prognosis. One of the drugs widely used in this cohort of patients is eribulin, which in addition to its antimitotic effect has
Externí odkaz:
https://doaj.org/article/04fa079dcbd74e2faf1af1a6011b0a93
Autor:
E. I. Kovalenko, E. V. Artamonova, L. V. Bolotina, L. A. Zhiliaeva, D. M. Ponomarenko, E. V. Karabina, G. Z. Mukhametshina, A. I. Khasanova, E. Yu. Ratner, A. R. Safarova, A. G. Manikhas, N. O. Popova, I. V. Evstigneeva, L. Yu. Vladimirova, L. V. Kramskaya, T. V. Karandeeva, I. R. Suslova, O. V. Romanchuk, V. E. Shikina, A. Yu. Povyshev, M. A. Osipov, E. M. Cherniakova, A. S. Dergunov, M. V. Volkonskiy, I. S. Chernov, I. E. Shumskaya, M. M. Fael, V. I. Garifullina, I. E. Gudkova
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 36-46 (2021)
Introduction. The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further treatment, as well as the opti
Externí odkaz:
https://doaj.org/article/ddfb182fcf6247f0b4a7bd188e53d850
Autor:
Liubov A. Tashireva, Nataliya O. Popova, Anna Yu. Kalinchuk, Viktor E. Goldberg, Elena I. Kovalenko, Elena V. Artamonova, Aleksey G. Manikhas, Dmitriy M. Ponomarenko, Nataliya V. Levchenko, Elena I. Rossokha, Svetlana Yu. Krasilnikova, Marina A. Zafirova, Evgeniy L. Choynzonov, Vladimir M. Perelmuter
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Triple-negative breast cancer has no specific treatment and unfavorable prognosis. Eribulin is one of the drugs widely used in this cohort of patients. In addition to its antimitotic effect, eribulin has an immunomodulant effect on the tumor microenv
Externí odkaz:
https://doaj.org/article/3ac581e67d2b4694a111faae60feb03c
Autor:
A. G. Manikhas, D. S. Pasekova
Publikováno v:
Опухоли женской репродуктивной системы, Vol 17, Iss 2 (2021)
Background. Standard treatment for hormone-dependent operable breast cancer includes surgery, hormone therapy (HT), and radiation therapy and chemotherapy (when necessary). Some elderly patients do not undergo surgery because of the high risk or refu
Externí odkaz:
https://doaj.org/article/db335559152b4128a4f23edc5d6631d5
Autor:
Irina V Kolyadina, Irina S Bulavina, Vladislav V Petkau, Natalia V Strakhova, Vera A Gorbunova, Elena I Kovalenko, Liudmila V Manziuk, Elena V Artamonova, Liudmila G Zhukova, Larisa V Bolotina, Inna P Gan'shina, Tatiana Iu Semiglazova, Aleksei G Manikhas, Natalia A Raevskaia, Ilia M Itkin, Svetlana V Khokhlova, Dmitrii V Filonenko, Viktor E Gol'dberg, Natalia O Popova, Dmitrii M Ponomarenko, Valentina E Shikina, Liubov I Vladimirova, Natalia M Tikhanovskaia, Elena V Karabina, Guzel Z Mukhametshina, Alfiia I Khasanova, Sufiia Z Safina, Mikhail V Shaidorov, Andrei E Orlov, Iuliia V Kostalanova, Natalia V Levchenko, Mikhail A Osipov, Tatiana V Karandeeva, Irina V Evstigneeva, Igor S Chernov, Dzheims Dzh Kolokolov, Anton Iu Povyshev, Alina S Shatokhina, Elena M Cherniakova, Oksana N Shkodenko, Evgeniia S Kuz'mina
Publikováno v:
Современная онкология, Vol 21, Iss 2, Pp 17-24 (2019)
Aim. Eribulin is an active cytostatic, associated with a wide range of mechanisms of antitumor effects, but eribulin efficiency and safety in patients with breast cancer (BC), associated with cerebral metastases are still poorly understood. Materials
Externí odkaz:
https://doaj.org/article/5f21fe71ca7c49f6a857b2579dfadccd
Autor:
Vera A Gorbunova, Irina V Kolyadina, Elena I Kovalenko, Liudmila V Manziuk, Elena V Artamonova, Liudmila G Zhukova, Larisa V Bolotina, Tat'iana Iu Semiglazova, Aleksei G Manikhas, Natal'ia A Raevskaia, Il'ia M Itkin, Dmitrii V Filonenko, Larisa A Zhilyaeva, Viktor E Gol'dberg, Natal'ia O Popova, Dmitrii M Ponomarenko, Valentina E Shikina, Irina R Suslova, Olga V Romanchuk, Dmitrii V Kozlov, Ali-Dzarakhmat S Rzaev, Vasilii V Marfutov, Irina I Andreiashkina, Liubov' I Vladimirova, Irina S Mitashok, Natal'ia M Tikhanovskaia, Elena V Karabina, Guzel' Z Mukhametshina, Al'fiia I Khasanova, Sufiia Z Safina, Mikhail V Shaidorov, Dmitrii A Morozov, Elena P Prokof'eva, Liudmila V Kramskaia, Tat'iana V Karandeeva, Irina V Evstigneeva, Elena G Ovchinnikova, Tat'iana P Klement'eva, Olga V Khrupalo, Elena V Tiuvinova, Viktor M Sherstnev, Igor' S Chernov, Dzheims Dzh Kolokolov, Elena A Gaisina, Natal'ia V Levchenko, Viacheslav A Chubenko, Anton Iu Povyshev, Inna V Iudina, Liudmila V Vorotilina, Tat'iana V Andreeva, Garnik S Tumanian, Anton E Koziakov, Liudmila A Gil'mutdinova, Mikhail A Osipov, Alina S Shatokhina, Alena A Vazhenina, Angelina S Chichkanova, Vladimir I Vladimirov, Aleksandr N Ivanov, Anna S Belokhvostova, Elena M Cherniakova, Elena A Tul'china, Svetlana A Maklashova, Oksana N Shkodenko, Iuliia V Kostalanova, Anna V Tarasova, Evgeniia S Kuz'mina
Publikováno v:
Современная онкология, Vol 21, Iss 1, Pp 12-23 (2019)
Aim. The aim of the study is to examine the efficacy and safety of eribulin in HER2-negative metastatic breast cancer (BC) in Russian clinical practice. Materials and methods. The analysis included 459 patients with advanced BC from 44 federal and mu
Externí odkaz:
https://doaj.org/article/fab8f79eb72a4ebeb4af3ca5e29be2e9